← All trials
NCT04359511
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2020
- First posted
- Apr 24, 2020
- Last posted
- May 20, 2020
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University Hospital, ToursLead sponsor
- University of RennesOverall official - principal investigator
- CH AMBOISEOverall official - principal investigator
- Centre Hospitalier de Blois -BLOISOverall official - principal investigator
- CH DE BOURGESOverall official - principal investigator
- Centre Hospitalier of ChartresOverall official - principal investigator
- CH DE CHATEAUROUXOverall official - principal investigator
- CH DE RDREUXOverall official - principal investigator
- CH DE VANNESOverall official - principal investigator
- Centre Hospitalier le MansOverall official - principal investigator
- CHR ORLEANSOverall official - principal investigator
- University Hospital, ToursOverall official - principal investigator
- CH SAINT MALOOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.